Table 2.

Mitotherapy in the central nervous system animal models.

	Study Reference	Experimental Model	Animal	Mito Source	Transplant	Route of Administration
Stroke	Huang et al., 2016 [21]	MCAO	Sprague Dawley rats	BHK-21 cells	Xenogeneic	Injection into ischemic striatum
	Zhang et al., 2019 [22]	MCAO	Sprague Dawley rats	Pectoralis major muscle	Autologous	Intracerebroventricular injection
Parkinson	Chang et al., 2016 [23]	6-OHDA	Sprague Dawley rats	PC12 cells and human osteosarcoma	Allogeneic and xenogeneic	Medial forebrain bundle injection
	Shi et al., 2017 [24]	MPP+	C57BL/6J mice	HepG2 cells	-	Intravenous injection
Schizophrenia	Robicsek et al., 2017 [27]	poly-I:C	Wistar rats	Whole brain	Allogeneic	Prefrontal cortex injection
Alzheimer’s disease	Nitzan et al., 2019 [29]	Amyloid-β brain injection	C57BL/6J mice	HeLa cells	-	Intravenous injection (tail)
Depression	Wang et al., 2019 [30]	LPS	ICR mice	Hippocampus	Allogeneic	Intravenous injection
Aging	Zhao et al., 2020 [31]	Aged mice (18 mo)	BABL/c mice	Liver	Allogeneic	Intravenous injection (tail)
Spinal cord	Gollihue et al., 2018 [40]	Spinal cord injury	Sprague Dawley rats	Soleus muscle	Allogeneic	Mediolateral gray matter of injury site
	Fang et al., 2019 [39]	Spinal cord ischemia	Sprague Dawley rats	Soleus muscle	Allogeneic	Intravenous injection (jugular)
Glaucoma	Nascimento-dos-Santos et al., 2020 [41]	Optic nerve crush	Lister hooded rats	Liver	Allogeneic	Intravitreal injection

Middle Cerebral Artery Occlusion (MCAO); 6-hydroxydopamine (6-OHDA); 1-methyl-4-phenylpyridinium (MPP⁺); Polyriboinosinic-polyribocytidylic acid (poly-I:C); Lipopolysaccharides (LPS).